Valeriy I. Vechorko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valeriy I. Vechorko has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Oleg V. Averkov
Pirogov Russian National Research Medical University, Moscow, Russia (O.A.).
20 shared publications - Dmitrij Alekseevitch Sychev
Petrovsky National Research Centre of Surgery; Russian Medical Academy of Continuous Professional Education
10 shared publications - Alexander Valerevich Kryukov
Russian Medical Academy of Continuous Professional Education; Filatov City Clinical Hospital No. 15
9 shared publications - Karin Badavievich Mirzaev
Petrovsky National Research Center of Surgery, Moscow 119435, Russia
8 shared publications - Natalia P. Denisenko
Russian Medical Academy of Continuous Professional Education. 2. Russian Scientific Center for Surgery named after Academician B.V. Petrovsky
8 shared publications - Dmitriy A. Doroshenko
N.I. Pirogov Russian National Research Medical University; Petrovsky National Research Center of Surgery
7 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 15 (5) , 151-165
EARLY OUTCOMES OF SURGICAL TREATMENT FOR INFECTIVE ENDOCARDITIS: A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF 200 PATIENTS
Highlights Infective endocarditis (IE) is associated with a high incidence of valvular destruction, heart failure, and systemic complications, emphasizing the importance of timely surgical intervention in specialized cardiac surgery centers. In this single-center study, the majority of patients required multivalve reconstructive or valve replacement procedures, reflecting the severity of structural valve damage associated with IE. Despite the complexity of the disease and the extensive nature of surgical interventions, the findings confirm the pivotal role of surgery in achieving infection control and correcting intracardiac complications in patients with infective endocarditis. Aim. To evaluate the early outcomes of surgical treatment for IE and to assess the structure of postoperative complications in patients undergoing surgery at a specialized cardiac surgery center. Methods. A single-center retrospective study included 200 consecutive patients with IE who underwent surgical treatment between 2013 and 2025. Clinical and demographic characteristics, echocardiographic findings, surgical variables, and early postoperative outcomes were analyzed. The primary endpoints were in-hospital mortality and postoperative complications. Results. The median age of the patients was 48 (38–63) years, and 75% were male. The most common indications for surgery were decompensated chronic heart failure (68.5%), uncontrolled infection (20.5%), and embolic events (15.5%). Vegetations were detected in 98% of patients, with a maximal size greater than 10 mm in 78% of cases. Valvular abscesses were identified in 16% of patients. Multivalve procedures were performed in 87% of cases, while valve replacement was required in 75.5% of patients. The median operative time was 190 (158–230) minutes, cardiopulmonary bypass time was 93.5 (76.8–118.3) minutes, and aortic cross-clamp time was 74 (60–91) minutes. In-hospital mortality was 22%. The most frequent postoperative complications included the need for inotropic or vasopressor support (44%), cardiovascular failure (38%), acute kidney injury (30.6%), respiratory failure (25.5%), postoperative atrial fibrillation (23%), sepsis (20%), and multiple organ dysfunction syndrome (22%). Stroke occurred in 5% of patients. Conclusions. Patients undergoing surgery for infective endocarditis are characterized by a high prevalence of valvular destruction, heart failure, and systemic complications. Despite the severity of the disease and the complexity of surgical procedures, surgery remains the cornerstone of treatment, providing control of the infectious process and correction of intracardiac lesions. Early outcomes are determined not only by surgical factors but also by disease severity at the time of intervention, highlighting the importance of timely diagnosis and early referral to specialized cardiac surgery centers.
- 31 October 2026
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 15 (5) , 151-165
Open AccessEARLY OUTCOMES OF SURGICAL TREATMENT FOR INFECTIVE ENDOCARDITIS: A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF 200 PATIENTS
Highlights Infective endocarditis (IE) is associated with a high incidence of valvular destruction, heart failure, and systemic complications, emphasizing the importance of timely surgical intervention in specialized cardiac surgery centers. In this single-center study, the majority of patients required multivalve reconstructive or valve replacement procedures, reflecting the severity of structural valve damage associated with IE. Despite the complexity of the disease and the extensive nature of surgical interventions, the findings confirm the pivotal role of surgery in achieving infection control and correcting intracardiac complications in patients with infective endocarditis. Aim. To evaluate the early outcomes of surgical treatment for IE and to assess the structure of postoperative complications in patients undergoing surgery at a specialized cardiac surgery center. Methods. A single-center retrospective study included 200 consecutive patients with IE who underwent surgical treatment between 2013 and 2025. Clinical and demographic characteristics, echocardiographic findings, surgical variables, and early postoperative outcomes were analyzed. The primary endpoints were in-hospital mortality and postoperative complications. Results. The median age of the patients was 48 (38–63) years, and 75% were male. The most common indications for surgery were decompensated chronic heart failure (68.5%), uncontrolled infection (20.5%), and embolic events (15.5%). Vegetations were detected in 98% of patients, with a maximal size greater than 10 mm in 78% of cases. Valvular abscesses were identified in 16% of patients. Multivalve procedures were performed in 87% of cases, while valve replacement was required in 75.5% of patients. The median operative time was 190 (158–230) minutes, cardiopulmonary bypass time was 93.5 (76.8–118.3) minutes, and aortic cross-clamp time was 74 (60–91) minutes. In-hospital mortality was 22%. The most frequent postoperative complications included the need for inotropic or vasopressor support (44%), cardiovascular failure (38%), acute kidney injury (30.6%), respiratory failure (25.5%), postoperative atrial fibrillation (23%), sepsis (20%), and multiple organ dysfunction syndrome (22%). Stroke occurred in 5% of patients. Conclusions. Patients undergoing surgery for infective endocarditis are characterized by a high prevalence of valvular destruction, heart failure, and systemic complications. Despite the severity of the disease and the complexity of surgical procedures, surgery remains the cornerstone of treatment, providing control of the infectious process and correction of intracardiac lesions. Early outcomes are determined not only by surgical factors but also by disease severity at the time of intervention, highlighting the importance of timely diagnosis and early referral to specialized cardiac surgery centers.
- Open Access
- 8 August 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (3) , 230-238
Comparison of the furosemide dose titration in the first day of treatment for decompensated chronic heart failure using urine output or urine sodium concentration monitoring
Aim . To compare the efficacy and safety of furosemide dose titration during the first 24 hours of treatment for decompensated heart failure (HF) with fluid retention, based on either urine volume or spot urinary sodium concentration. Material and methods. This prospective, randomised, open-label, single-center study included 110 patients with decompensated HF, signs of fluid retention, and regular furosemide use. The initial intravenous furosemide dose was twice the outpatient dose. In the first group (n=55), efficacy was assessed by 6-hour urine output: if ≥100 mL/h, the same dose was repeated after 12 hours; if response was insufficient, the dose was doubled every 6 hours until the target urine volume was achieved. In the second group (n=55), the 2-hour spot urinary sodium concentration was used: if ≥50 mmol/L, the same dose was repeated after 12 hours; if Results . Mean patient age was 74±9.2 years; male proportion was 52.7%. The median intravenous furosemide dose in the first 24 hours was 160 mg in the urine sodiumguided group versus 80 mg in the urine volumeguided group (pConclusion . In patients hospitalised with decompensated HF, furosemide dose titration during the first 24 hours based on urinary sodium concentration (compared to the urine volumebased approach) was associated with the use of higher doses, leading to greater weight loss, better congestion relief, an
- 8 August 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (3) , 230-238
Open AccessComparison of the furosemide dose titration in the first day of treatment for decompensated chronic heart failure using urine output or urine sodium concentration monitoring
Aim . To compare the efficacy and safety of furosemide dose titration during the first 24 hours of treatment for decompensated heart failure (HF) with fluid retention, based on either urine volume or spot urinary sodium concentration. Material and methods. This prospective, randomised, open-label, single-center study included 110 patients with decompensated HF, signs of fluid retention, and regular furosemide use. The initial intravenous furosemide dose was twice the outpatient dose. In the first group (n=55), efficacy was assessed by 6-hour urine output: if ≥100 mL/h, the same dose was repeated after 12 hours; if response was insufficient, the dose was doubled every 6 hours until the target urine volume was achieved. In the second group (n=55), the 2-hour spot urinary sodium concentration was used: if ≥50 mmol/L, the same dose was repeated after 12 hours; if Results . Mean patient age was 74±9.2 years; male proportion was 52.7%. The median intravenous furosemide dose in the first 24 hours was 160 mg in the urine sodiumguided group versus 80 mg in the urine volumeguided group (pConclusion . In patients hospitalised with decompensated HF, furosemide dose titration during the first 24 hours based on urinary sodium concentration (compared to the urine volumebased approach) was associated with the use of higher doses, leading to greater weight loss, better congestion relief, an
- 27 May 2026
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 19 (3)
Single-stage treatment of traumatic aortic injury combined with tricuspid insufficiency
Traumatic aortic injury represents a critical life-threatening condition characterized by high mortality rates. This pathology ranks as the second leading cause of death among patients with polytrauma surpassed only by blunt traumatic brain injury. High mortality rate is attributed to significant risk of massive bleeding, hemorrhagic shock, and subsequent multiple organ failure resulting from aortic disruption. These factors collectively contribute to extremely poor prognosis in the absence of timely and appropriate treatment. This article presents successful management of a patient with post-traumatic aortic injury combined with tricuspid insufficiency. The authors demonstrate effective hybrid approach.
- 27 May 2026
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 19 (3)
Single-stage treatment of traumatic aortic injury combined with tricuspid insufficiency
Traumatic aortic injury represents a critical life-threatening condition characterized by high mortality rates. This pathology ranks as the second leading cause of death among patients with polytrauma surpassed only by blunt traumatic brain injury. High mortality rate is attributed to significant risk of massive bleeding, hemorrhagic shock, and subsequent multiple organ failure resulting from aortic disruption. These factors collectively contribute to extremely poor prognosis in the absence of timely and appropriate treatment. This article presents successful management of a patient with post-traumatic aortic injury combined with tricuspid insufficiency. The authors demonstrate effective hybrid approach.
- 18 February 2026
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 19 (1)
Surgical removal of a floating thrombus in aortic arch
A floating thrombus in aortic arch represents a rare but highly dangerous disease with significant risk of systemic embolism resulting in ischemic stroke, critical ischemia of abdominal organs and limbs. This article presents successful surgical removal of a giant floating thrombus from aortic arch using cardiopulmonary bypass and circulatory arrest under moderate hypothermia. The results highlight the efficacy of active surgical approach for this rare and dangerous condition.
- 18 February 2026
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 19 (1)
Surgical removal of a floating thrombus in aortic arch
A floating thrombus in aortic arch represents a rare but highly dangerous disease with significant risk of systemic embolism resulting in ischemic stroke, critical ischemia of abdominal organs and limbs. This article presents successful surgical removal of a giant floating thrombus from aortic arch using cardiopulmonary bypass and circulatory arrest under moderate hypothermia. The results highlight the efficacy of active surgical approach for this rare and dangerous condition.
- Open Access
- 14 January 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (5) , 441-448
The role of CYP2C19 gene nucleotide sequence variants in assessing response to P2Y12 receptor inhibitor antiplatelet therapy in old patients with acute coronary syndrome
Aim . To assess the association between carrying CYP2C19 polymorphic variants and response to antiplatelet therapy, evaluated by residual platelet reactivity (Platelet Reactivity Units, PRU), in patients from different age groups. Material and methods . The study included 140 patients with ACS receiving antiplatelet therapy with P2Y12 receptor inhibitors. The main group consisted of 70 patients aged 75 to 90 years (senile age), 35 taking clopidogrel, and 35 taking ticagrelor. The control group consisted of 70 patients aged 45 to 74 years (old and middle age), 35 taking clopidogrel, and 35 taking ticagrelor. The antiplatelet effect of therapy was assessed by studying non-stabilized whole blood using the VerifyNow point-ofcare assay. Carriage of the CYP2C19*2 and CYP2C19*3 alleles was determined using commercial reagent kits (Sintol LLC, Russia), and CYP2C19*17 was determined using commercial kits (Applied Biosystems, USA). Results . The influence of CYP2C19 genetic variability on residual platelet aggregation was evaluated in elderly patients compared to patients of old and middle age. PRU values in the main group (senile age) (120.9 (48.5; 205.0)) on day 2 were statistically significantly higher (p=0.03) than in the control group (old and middle age) (96.06 (17.0; 174.5)). The same trend was observed in all subgroup comparison depending on the drug used: PRU values were statistically significantly higher in the main group of patients. Genotype distribution corresponded to the Hardy-Weinburg law for CYP2C19*17 and CYP2C19*2 except for CYP2C9*3. In control group patients receiving ticagrelor, carriage of the T allele (CYP2C19*17 locus) was statistically significantly associated with lower PRU levels (p=0.023). Furthermore, in the main study group among patients with PRU>208 receiving clopidogrel, carriers of the minor T allele at the CYP2C19*17 locus were statistically significantly more frequent (p=0.022) (CC genotype in 32% of patients, CT/TT genotypes in 80%). Conclusion . Comparison of the main (senile age) and control (old and middle age) groups revealed that elderly age is associated with higher PRU values. A similar pattern was found when analyzing the main and control groups by subgroups depending on the drug taken: the proportion of patients with PRU values >208 was statistically significantly higher among patients from the main group (senile age). The obtained results regarding the carriage of the minor T allele at the CYP2C19*17 locus and PRU values in the main group could be associated with the phenomenon of phenoconversion, comorbidity, and polypharmacy in elderly patients.
- 14 January 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (5) , 441-448
Open AccessThe role of CYP2C19 gene nucleotide sequence variants in assessing response to P2Y12 receptor inhibitor antiplatelet therapy in old patients with acute coronary syndrome
Aim . To assess the association between carrying CYP2C19 polymorphic variants and response to antiplatelet therapy, evaluated by residual platelet reactivity (Platelet Reactivity Units, PRU), in patients from different age groups. Material and methods . The study included 140 patients with ACS receiving antiplatelet therapy with P2Y12 receptor inhibitors. The main group consisted of 70 patients aged 75 to 90 years (senile age), 35 taking clopidogrel, and 35 taking ticagrelor. The control group consisted of 70 patients aged 45 to 74 years (old and middle age), 35 taking clopidogrel, and 35 taking ticagrelor. The antiplatelet effect of therapy was assessed by studying non-stabilized whole blood using the VerifyNow point-ofcare assay. Carriage of the CYP2C19*2 and CYP2C19*3 alleles was determined using commercial reagent kits (Sintol LLC, Russia), and CYP2C19*17 was determined using commercial kits (Applied Biosystems, USA). Results . The influence of CYP2C19 genetic variability on residual platelet aggregation was evaluated in elderly patients compared to patients of old and middle age. PRU values in the main group (senile age) (120.9 (48.5; 205.0)) on day 2 were statistically significantly higher (p=0.03) than in the control group (old and middle age) (96.06 (17.0; 174.5)). The same trend was observed in all subgroup comparison depending on the drug used: PRU values were statistically significantly higher in the main group of patients. Genotype distribution corresponded to the Hardy-Weinburg law for CYP2C19*17 and CYP2C19*2 except for CYP2C9*3. In control group patients receiving ticagrelor, carriage of the T allele (CYP2C19*17 locus) was statistically significantly associated with lower PRU levels (p=0.023). Furthermore, in the main study group among patients with PRU>208 receiving clopidogrel, carriers of the minor T allele at the CYP2C19*17 locus were statistically significantly more frequent (p=0.022) (CC genotype in 32% of patients, CT/TT genotypes in 80%). Conclusion . Comparison of the main (senile age) and control (old and middle age) groups revealed that elderly age is associated with higher PRU values. A similar pattern was found when analyzing the main and control groups by subgroups depending on the drug taken: the proportion of patients with PRU values >208 was statistically significantly higher among patients from the main group (senile age). The obtained results regarding the carriage of the minor T allele at the CYP2C19*17 locus and PRU values in the main group could be associated with the phenomenon of phenoconversion, comorbidity, and polypharmacy in elderly patients.
- 25 November 2025
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 11,p. 129-133
Successful repeated endovascular procedure for TIPS thrombosis
Transjugular intrahepatic portosystemic shunt (TIPS) is a minimally invasive and effective treatment for gastrointestinal variceal bleeding and refractory ascites associated with portal hypertension. However, TIPS dysfunction occurs for various reasons and can lead to recurrent complications. In such cases, repeated endovascular intervention can be performed for portal hypertension. This article presents one of the methods of endovascular correction (Y-stenting) for TIPS thrombosis.
- 25 November 2025
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 11,p. 129-133
Successful repeated endovascular procedure for TIPS thrombosis
Transjugular intrahepatic portosystemic shunt (TIPS) is a minimally invasive and effective treatment for gastrointestinal variceal bleeding and refractory ascites associated with portal hypertension. However, TIPS dysfunction occurs for various reasons and can lead to recurrent complications. In such cases, repeated endovascular intervention can be performed for portal hypertension. This article presents one of the methods of endovascular correction (Y-stenting) for TIPS thrombosis.
- Open Access
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 40-47
Pharmacogenetic aspects of the efficacy of nonsteroidal anti-inflammatory drugs and opioid analgesics for postoperative pain relief after total joint arthroplasty
Objective: to investigate possible associations between genetic, clinical, laboratory, and demographic parameters and the level of pain in the early postoperative (p/o) period, the need for opioid analgesics, and gastrointestinal symptoms in patients who underwent primary total knee (TKR) or hip replacement (THR).Material and methods. Sixty-one patients hospitalized for THR or TKR were included in the study. P/o pain relief was achieved using nonsteroidal anti-inflammatory drugs (NSAIDs) – ketoprofen or ketorolac – with tramadol prescribed "on demand." Pain was assessed in all patients using the numeric rating scale (NRS) on postoperative days 1–5. The amount of opioid analgesics used during hospitalization was recorded. Gene polymorphisms of CYP2C9, CYP2C8, PTGS1, PTGS2, ABCB1, CYP2D6, OPRM1, COMT, and C3orf20 were analyzed using real-time polymerase chain reaction.Results and discussion. Patients with the AC genotype of CYP2C9*3 experienced less intense pain on postoperative day 1 (4.5±1.0 vs. 7.0±2.3; p=0.03) and required fewer opioids during hospitalization (20.0±11.5 vs. 28.0±7.4 morphine equivalent units; p=0.04) compared to those with the AA genotype. Carriers of the CC genotype of the rs1045642 polymorphism of the ABCB1 gene reported less pain on day 5 (1.5±0.7 vs. 3.7±1.2; p=0.04) than those with the CT genotype. Patients with the AA genotype of rs1799971 in the OPRM1 gene required more opioids in p/o period than those with AG + GG genotypes (28.4±7.1 vs. 21.6±9.8 morphine equivalent units; p=0.03). Patients with the GG genotype of rs12496846 in the C3orf20 gene experienced more intense pain on p/o day 4 (6.0±1.41) than those with the AA genotype (2.60±1.50; p=0.002).Conclusion. Following THR and TKR, pain intensity and/or opioid use were associated with patients’ pharmacogenetic profiles in CYP2C9, ABCB1, OPRM1, and C3orf20.
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 40-47
Open AccessPharmacogenetic aspects of the efficacy of nonsteroidal anti-inflammatory drugs and opioid analgesics for postoperative pain relief after total joint arthroplasty
Objective: to investigate possible associations between genetic, clinical, laboratory, and demographic parameters and the level of pain in the early postoperative (p/o) period, the need for opioid analgesics, and gastrointestinal symptoms in patients who underwent primary total knee (TKR) or hip replacement (THR).Material and methods. Sixty-one patients hospitalized for THR or TKR were included in the study. P/o pain relief was achieved using nonsteroidal anti-inflammatory drugs (NSAIDs) – ketoprofen or ketorolac – with tramadol prescribed "on demand." Pain was assessed in all patients using the numeric rating scale (NRS) on postoperative days 1–5. The amount of opioid analgesics used during hospitalization was recorded. Gene polymorphisms of CYP2C9, CYP2C8, PTGS1, PTGS2, ABCB1, CYP2D6, OPRM1, COMT, and C3orf20 were analyzed using real-time polymerase chain reaction.Results and discussion. Patients with the AC genotype of CYP2C9*3 experienced less intense pain on postoperative day 1 (4.5±1.0 vs. 7.0±2.3; p=0.03) and required fewer opioids during hospitalization (20.0±11.5 vs. 28.0±7.4 morphine equivalent units; p=0.04) compared to those with the AA genotype. Carriers of the CC genotype of the rs1045642 polymorphism of the ABCB1 gene reported less pain on day 5 (1.5±0.7 vs. 3.7±1.2; p=0.04) than those with the CT genotype. Patients with the AA genotype of rs1799971 in the OPRM1 gene required more opioids in p/o period than those with AG + GG genotypes (28.4±7.1 vs. 21.6±9.8 morphine equivalent units; p=0.03). Patients with the GG genotype of rs12496846 in the C3orf20 gene experienced more intense pain on p/o day 4 (6.0±1.41) than those with the AA genotype (2.60±1.50; p=0.002).Conclusion. Following THR and TKR, pain intensity and/or opioid use were associated with patients’ pharmacogenetic profiles in CYP2C9, ABCB1, OPRM1, and C3orf20.
- 30 April 2025
- Published by Federal Scientific Center for Hygiene F.F.Erisman in Health Care of the Russian Federation
- Vol. 69 (2) , 111-116
Medical triage of victims in emergency situations: skills in medical specialists of non-staff mobile medical units of civil defense
Introduction. The most important element of the system of medical and evacuation support for victims in emergency situations (ES) is medical triage. Scientific works indicate significant shortcomings in the possession of medical triage skills in outpatient and polyclinic doctors. Purpose of the study. To evaluate the possibilities of involving surgical doctors from the Moscow Municipal Emergency Stationary Complex (ESC) in work in an unofficial mobile medical unit (MMU) of civil defense in the elimination of medical and sanitary consequences of large-scale emergencies in peacetime and wartime. Materials and methods. Using the timing of medical triage of simulated victims in emergencies by triage teams of ESC surgical doctors, there was detected average time spent on medical triage of one victim of moderate (severe) severity admitted to the MMU. An analysis of the adopted triage decisions regarding victims was conducted in accordance with the data of the simulation coupons. A comparative analysis of the capabilities of the triage teams of ESC doctors and city polyclinics was conducted. Results. The capacity of two ESC teams per hour of work will be 54 cases, for 12 hours — 648 patients. A comparative analysis of the capacity of two ESC teams of doctors for 12 hours of work showed their efficiency to be of 1.8 times higher, compared to the work of three teams of doctors of municipal polyclinics. 10.0% of incorrect sorting decisions were identified, which did not affect the quality of medical sorting. Research limitations. The study materials are limited to the results of scientific research of the Moscow Territorial Scientific and Practical Center for Disaster Medicine, obtained in 2024 during the research tactical and special exercise based on the Municipal Clinical Hospital No. 15 named after O.M. Filatov. Conclusion. The results of the study demonstrated the high potential of the ESC physician teams. Triage decisions on the evacuation of victims to specialized hospitals with the provision of medical care by ambulance teams during its implementation are justified practical decisions. It is advisable to consider the managerial model of the MMU with the inclusion of two triage teams of ESC physicians in the structure.
- 30 April 2025
- Published by Federal Scientific Center for Hygiene F.F.Erisman in Health Care of the Russian Federation
- Vol. 69 (2) , 111-116
Medical triage of victims in emergency situations: skills in medical specialists of non-staff mobile medical units of civil defense
Introduction. The most important element of the system of medical and evacuation support for victims in emergency situations (ES) is medical triage. Scientific works indicate significant shortcomings in the possession of medical triage skills in outpatient and polyclinic doctors. Purpose of the study. To evaluate the possibilities of involving surgical doctors from the Moscow Municipal Emergency Stationary Complex (ESC) in work in an unofficial mobile medical unit (MMU) of civil defense in the elimination of medical and sanitary consequences of large-scale emergencies in peacetime and wartime. Materials and methods. Using the timing of medical triage of simulated victims in emergencies by triage teams of ESC surgical doctors, there was detected average time spent on medical triage of one victim of moderate (severe) severity admitted to the MMU. An analysis of the adopted triage decisions regarding victims was conducted in accordance with the data of the simulation coupons. A comparative analysis of the capabilities of the triage teams of ESC doctors and city polyclinics was conducted. Results. The capacity of two ESC teams per hour of work will be 54 cases, for 12 hours — 648 patients. A comparative analysis of the capacity of two ESC teams of doctors for 12 hours of work showed their efficiency to be of 1.8 times higher, compared to the work of three teams of doctors of municipal polyclinics. 10.0% of incorrect sorting decisions were identified, which did not affect the quality of medical sorting. Research limitations. The study materials are limited to the results of scientific research of the Moscow Territorial Scientific and Practical Center for Disaster Medicine, obtained in 2024 during the research tactical and special exercise based on the Municipal Clinical Hospital No. 15 named after O.M. Filatov. Conclusion. The results of the study demonstrated the high potential of the ESC physician teams. Triage decisions on the evacuation of victims to specialized hospitals with the provision of medical care by ambulance teams during its implementation are justified practical decisions. It is advisable to consider the managerial model of the MMU with the inclusion of two triage teams of ESC physicians in the structure.
- Open Access
- 10 February 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 69 (9-10) , 47-55
A Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir
Favipiravir is an antiviral drug that has become widely used for the etiotropic treatment of COVID-19. According to a number of studies, the incidence of adverse reactions during favipiravir therapy reaches 93%, and the most common adverse reaction is an increase in the level of liver enzymes in the blood. The aim was to study the influence of gender-age, clinical-anamnestic and pharmacogenetic factors on the development of drug-induced liver injury during favipiravir therapy in hospitalized patients with COVID-19. Material and methods. The study included 150 hospitalized patients with COVID-19 receiving favipiravir therapy. Patients were divided into 2 groups: group 1 — 31 patients who developed an increase in alanine transaminase levels multiple of two upper limits of normal or more against the background of favipiravir therapy; group 2 (control) — 119 patients who did not develop this adverse reaction. A retrospective analysis of case histories was performed in patients of both groups, and a pharmacogenetic study was performed in 14 patients of group 1 and 71 patients of group 2. Based on the data obtained, the association of clinical, laboratory, pharmacological, and pharmacogenetic parameters with the development of drug-induced liver injury during favipiravir therapy was studied. Results. There were significantly more younger individuals in the group of patients who developed drug-induced liver injury than in the control group (60.48±15.93 and 66.38±14.23 years respectively, P=0.047), with a lower level of lymphocytes in the blood (1.103±0.644 and 1.537±1.866 109/l respectively, P=0.022) and a higher level of interleukin-6 (288.019±344.794 and 152.490±274.67 pg/ml respectively, P=0.045), as well as those receiving cephalosporin therapy (OR=4.891, CI=1.610–14.862, 2χ =9.047, P=0.003), beta-blockers (OR=0.416, CI=0.177–0.978, χ²=4.190, P=0.041), diuretics (OR=0.328, CI=0.107–1.006, P=0.043), interleukin inhibitors (OR=4.891, CI=1.610–14.862, χ²=9.047, P=0.003) and those who underwent repeated administration of interleukin inhibitors (OR=6.884, CI=2.609–18.168, χ²=18.048, P=0.000). Conclusions. Younger age, lower lymphocyte counts, and higher interleukin-6 levels in the blood, as well as concomitant therapy with cephalosporins, betablockers, diuretics, and interleukin inhibitors, including repeated administration of interleukin inhibitors, increase the likelihood of developing drug-induced liver injury during favipiravir therapy. Therefore, it is necessary to take these factors into account when prescribing favipiravir therapy, conduct more careful monitoring of clinical and laboratory indicators of liver damage, and develop personalized approaches to the treatment of patients with COVID-19.
- 10 February 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 69 (9-10) , 47-55
Open AccessA Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir
Favipiravir is an antiviral drug that has become widely used for the etiotropic treatment of COVID-19. According to a number of studies, the incidence of adverse reactions during favipiravir therapy reaches 93%, and the most common adverse reaction is an increase in the level of liver enzymes in the blood. The aim was to study the influence of gender-age, clinical-anamnestic and pharmacogenetic factors on the development of drug-induced liver injury during favipiravir therapy in hospitalized patients with COVID-19. Material and methods. The study included 150 hospitalized patients with COVID-19 receiving favipiravir therapy. Patients were divided into 2 groups: group 1 — 31 patients who developed an increase in alanine transaminase levels multiple of two upper limits of normal or more against the background of favipiravir therapy; group 2 (control) — 119 patients who did not develop this adverse reaction. A retrospective analysis of case histories was performed in patients of both groups, and a pharmacogenetic study was performed in 14 patients of group 1 and 71 patients of group 2. Based on the data obtained, the association of clinical, laboratory, pharmacological, and pharmacogenetic parameters with the development of drug-induced liver injury during favipiravir therapy was studied. Results. There were significantly more younger individuals in the group of patients who developed drug-induced liver injury than in the control group (60.48±15.93 and 66.38±14.23 years respectively, P=0.047), with a lower level of lymphocytes in the blood (1.103±0.644 and 1.537±1.866 109/l respectively, P=0.022) and a higher level of interleukin-6 (288.019±344.794 and 152.490±274.67 pg/ml respectively, P=0.045), as well as those receiving cephalosporin therapy (OR=4.891, CI=1.610–14.862, 2χ =9.047, P=0.003), beta-blockers (OR=0.416, CI=0.177–0.978, χ²=4.190, P=0.041), diuretics (OR=0.328, CI=0.107–1.006, P=0.043), interleukin inhibitors (OR=4.891, CI=1.610–14.862, χ²=9.047, P=0.003) and those who underwent repeated administration of interleukin inhibitors (OR=6.884, CI=2.609–18.168, χ²=18.048, P=0.000). Conclusions. Younger age, lower lymphocyte counts, and higher interleukin-6 levels in the blood, as well as concomitant therapy with cephalosporins, betablockers, diuretics, and interleukin inhibitors, including repeated administration of interleukin inhibitors, increase the likelihood of developing drug-induced liver injury during favipiravir therapy. Therefore, it is necessary to take these factors into account when prescribing favipiravir therapy, conduct more careful monitoring of clinical and laboratory indicators of liver damage, and develop personalized approaches to the treatment of patients with COVID-19.
- 1 January 2025
- Published by Geotar-Media Publishing Group in Angiology and vascular surgery
- Vol. 31 (3) , 154-159
TIPS dysfunction: what has to be done?
Дисфункция шунта после трансъюгулярного внутрипеченочного портосистемного шунтирования: что делать?
- 1 January 2025
- Published by Geotar-Media Publishing Group in Angiology and vascular surgery
- Vol. 31 (3) , 154-159
TIPS dysfunction: what has to be done?
Дисфункция шунта после трансъюгулярного внутрипеченочного портосистемного шунтирования: что делать?